Products for Research Use Only
RegisterLogin

Tanespimycin (Standard)

CAT: 0804-HY-10211R-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10211R-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tanespimycin (Standard) is the analytical standard of Tanespimycin. This product is intended for research and analytical applications. Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90[1][5]. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression[3].
CAS Number
75747-14-7
Product Name Alternative
17-AAG (Standard) ; NSC 330507 (Standard) ; CP 127374 (Standard)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Apoptosis; Autophagy; Bacterial; HSP; Mitophagy; Reference Standards
Related Pathways
Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Others
Field of Research
Cancer; Infection
Purity
98.72
Smiles
O=C(C(NC(/C(C)=C/C=C\[C@H](OC)[C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](C1)C)OC)O)C)OC(N)=O)=O)=CC2=O)C1=C2NCC=C
Molecular Formula
C31H43N3O8
Molecular Weight
585.69
Precautions
H302, H315, H319, H335
References & Citations
[1]Solit DB, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.Clin Cancer Res, 2002, 8 (5), 986-993.|[2]Raja, Srikumar M., et al. 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biology & Therapy (2008), 7 (10), 163|[3]Zhang J, et al. The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells.Clin Exp Med. 2012 Sep 7.|[4]Newman B, et al. HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells.Cancer Res. 2012 Sep 1;72 (17) :4551-61. Epub 2012 Jun 29.|[5]Kamal A, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003 Sep 25;425 (6956) :407-10.|[6]Enomoto A, et al. The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition. Eur J Cancer. 2013 Nov;49 (16) :3547-58.
Shipping Conditions
Blue Ice
Storage Conditions
4°C, sealed storage, away from light and moisture
Scientific Category
Reference Standards

Related Products

CatalogName
HY-10211-01Tanespimycin
HY-10211STanespimycin-d5
HY-P2274RArgifin (Standard)
HY-N9362REmodinanthrone (Standard)
HY-N7948RIsomaltotetraose (Standard)
HY-N7640RDeoxylimonin (Standard)
HY-N7617RToralactone (Standard)
HY-N7541RAntrodin A (Standard)
HY-N6739RBeauvericin (Standard)
HY-N6687RCalcimycin (Standard)

Alternative Products

CatalogName
T6290-01Tanespimycin
MBS575013117-AAG (Tanespimycin)
S1141-1gTanespimycin (17-AAG)
A10010-100Tanespimycin (17-AAG, KOS953) 100mg
A10010-10Tanespimycin (17-AAG, KOS953) 10mg
A10010-50Tanespimycin (17-AAG, KOS953) 50mg
A10010-200Tanespimycin (17-AAG, KOS953) 200mg
A10010-25Tanespimycin (17-AAG, KOS953) 25mg
A10010-10mM-DTanespimycin (17-AAG, KOS953) 10mM * 1mL in DMSO
DLL-0011-2MLTanespimycin (17-AAG) Liposomes, Formulation XT28.1

Popular Products